骨松Ⅱ号治疗绝经后骨质疏松症临床生化指标观察

目的：评估骨松Ⅱ号治疗绝经后骨质疏松症的疗效，并试图揭示其机理。方法：以３５例年龄４９－６２岁，绝经时间５．６年的绝经后骨质疏松妇女为治疗对象，于治疗后６－９个月、１－２年分期随访。疗程６个月－２年１个月不等，平均疗程为１年２个月。治疗前后作血雌二醇（Ｅ２）、睾酮（Ｔ）、晨尿Ｃａ／Ｃｒ、２４ｈ尿Ｃａ／Ｃｒ、２４ｈ尿Ｅ２、２４ｈ尿羟脯氨酸（ＨＯＰ）等生化指标的测定。结果：治疗６－９个月及治疗１－２年

Clinical biochemical observations on treatment for postmenopausal osteoporosis with gusong-II]

OBJECTIVE: To evaluate the curative effect of Cusong II for postmenopausal osteoporosis, and try to reveal its mechanism. METHODS: Thirty-five women, 49 to 62 years old, with 5.6 years menopause were treated as the subjects and followed for 6-9 months, 1-2 years. The course of treatment ranged from 6 months to 2 years and 1 month, and the average treatment period was 1 year and 2 months. Some related biochemical markers, such as serum estradiol (E2), testosterone (T), lasting morning urinary Ca/Cr, 24 h urinary Ca/Cr, 24 h urinary E2, 24 h urinary hydroxyproline (HOP), were measured before and after treatment. RESULTS: After 6-9 months or 1-2 years, the levels of serum E2 and 24 h urinary E2 were raised significantly, while the levels of serum T and urinary Ca/Cr reduced evidently after 1- or 2- year treatment. The levels of serum E2 and 24 h urinary E2 were significantly correlated with levels of lasting morning urinary and 24 h urinary Ca/Cr, serum T, 24 h urinary HOP respectively. CONCLUSION: Gusong-II could elevate the serum E2 levels of postmenopausal women, reduce the discharge of urinary Ca/Cr and HOP, inhibit the bone resorption. The rose of the serum E2 level might be correlated with the conversion of T into E2.